. This three-part webinar series, “Advances in RNA-based Biomarker Development for Precision Oncology”, will highlight trends in RNA-based biomarker development for precision oncology, ranging from the use of gene expression signatures in the development cancer therapies, to the development of RNA-based companion diagnostics, to novel applications for RNA-based biomarkers in cancer treatment. Part 1 is August 24th, with Parts 2 and 3 September 10th and October 8th. Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success. Date: August 24, 2020 Time: 10:00 am PDT / 1:00 pm EDT REGISTER HERE Speakers will detail a range of topics, including how expression-based subtyping can eclipse DNA targeted panel technologies in determining patient’s likely response to treatment; the use of clinical subtypes and custom response signatures to select the right therapy for the right patient to improve treatment responses; and the identification of new tumor types for therapies.

Joel Parker of the University of North Carolina at Chapel Hill will discuss the identification of diverse molecular phenotypes with RNA-seq, focusing on expressed mutations, immune phenotypes, and viral detection and quantification.

Kirk Beebe of GeneCentric Therapeutics will follow with a presentation outlining the use of RNA-seq for bolstering drug development programs by circumventing mutational status and deciphering the functional expression of tumors. In particular, he will discuss how bulk tumor sequencing offers the ability to simultaneously assess diverse members of the tumor microenvironment such as cancer and immune cells and will share details of how this approach has been applied in both targeted and immunotherapies.

REGISTER HERE